ARIAD Pharmaceuticals (ARIA) : Thursdays money flow data in ARIAD Pharmaceuticals (ARIA) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.8 million, whereas, $0.28 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 2.82, in favor of the bulls. The total money flow into the stock was $0.52 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0.59 million. The total value of block trades done on upticks was $0.59 million. ARIAD Pharmaceuticals (ARIA) fell $0.01 and traded at $7.37, down -0.07% for the day, over previous days close. On a weekly basis, the shares are -1.67% over the previous weeks close.
ARIAD Pharmaceuticals (ARIA) : The highest level ARIAD Pharmaceuticals (ARIA) is projected to reach is $13 for the short term and the lowest estimate is at $8. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $10.4 and the possibility the share price can swing is $2.07. The stock has recorded a 20-day Moving Average of 4.17% and the 50-Day Moving Average is 4.96%.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $7.45 on Thursday but the bulls could not build on the opening and the stock topped out at $7.47 for the day. The stock traded down to $7.21 during the day, due to lack of any buying support eventually closed down at $7.34 with a loss of -0.41% for the day. The stock had closed at $7.37 on the previous day. The total traded volume was 1,972,793 shares.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).